

Human I-309



www.mesoscale.com®

Ordering Information

MSD Customer Service Phone: 1-240-314-2795 : 1-301-990-2776 Email: CustomerService@ mesoscale.com

Scientific Support

Phone: 1-240-314-2798 Email: ScientificSupport@ mesoscale.com


Company Address

MESO SCALE DISCOVERY® A division of Meso Scale Diagnostics, LLC. 1601 Research Boulevard Rockville, MD 20850-3173 USA

Product Options	Catalog Number	Description	
Multiplex	K15067M, K25067M K151AEM, K251AEM K151ACM, K251ACM	U-PLEX Biomarker Group 1 (human) U-PLEX Immuno-Oncology Group 1 (human) U-PLEX Metabolic Group 1 (human)	
Singleplex	K151UYK-1/-2/-4	U-PLEX Human I-309 Assay with SECTOR™ plates	
	K151UYK-21/-22/-24	U-PLEX Human I-309 Assay with QuickPlex® plates	
	K251UYK-2/-4	U-PLEX Human I-309 Assay with 384-well plates	
Antibody Set	B21UY-2/-3	U-PLEX Human I-309 Antibody Set	
Protocol	U-PLEX Product Inserts are available at http://www.mesoscale.com		

The U-PLEX® platform was designed to provide ultimate flexibility for detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX Human I-309 Assay tested on U-PLEX 96-well SECTOR plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available on 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

Representative Calibration Curve and Sensitivity



Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)	
I-309	6.8	6.4-7.7	

The Calibrator curve was fitted with a 4-parameter logistic model with a $1/Y^2$ weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5 standard deviations above the background (zero Calibrator).

Precision

Control	Average Conc. (pg/mL)	Average Intra-run Conc. (%CV)	Inter-run Conc. (%CV)
High	516	5.8	14.5
Mid	262	6.0	12.5
Low	127	6.1	13.7

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

For Research Use Only. Not for use in diagnostic procedures.





MSD® U-PLEX Human I-309

Tested Samples

Sample Type	Serum (N=10)	Plasma (N=10)	
Median (pg/mL)	8.8	8.0	
Range (pg/mL)	ND-11	ND-18	
% Detected	70	80	

Normal serum and plasma samples were diluted 2-fold prior to the assay. ND = non-detectable (<LLOD)

Dilution Linearity

Serum			EDTA Plasma		
Fold Dilution		% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range
2	122	114-130	2	138	133-143
4	150	138-158	4	176	156-189
8	165	148-178	8	216	174-260

Normal human serum and EDTA plasma were spiked with Calibrator and tested at different dilutions. Undiluted samples were tested to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

Spike Recovery

	Ser	um	EDTA I	Plasma
Spike Level	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
High	65	57-68	54	52-59
Mid	72	62-82	69	64-78
Low	92	81-102	85	68-93

Normal serum and plasma were spiked with Calibrator at 3 levels. Undiluted samples were tested to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

Specificity

To assess specificity, the I-309 Antibody Set was tested individually against a larger panel of analytes for nonspecific binding (APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, BDNF, C-Peptide, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, Desghrelin, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FGF-23, FLT3L, Fractalkine, FSH, Galectin-9, G-CSF, GITRL/TNFSF18, GITR/TNFRSF18, Ghrelin (Ser3-octanoylated), gp130 (soluble), GIP (1–42), GIP (3–42), GLP-1 (7–36), GLP-1 (9–36), GM-CSF, Granzyme A, Granzyme B, GRO- α , HAVCR2/TIM-3, HVEM/TNFRSF14, ICOS, ICOS-L/B7-H2, I-309, IFN- α 2a, IFN- α 4, IFN- α 7, IL-1 α 8, IL-1 α 8, IL-1 α 8, IL-1 α 8, IL-1 α 9, IL-1 α 9, IL-1 α 9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN- α 1, IL-31, IL-33, Insulin, IP-10, LAG3, Leptin, LH, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1 α 9, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, SDF-1 α 9, Tie-2, TIGIT, TLR1, TNF- α 9, TNF-RI, TNF-RII, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/FIt-1, and YKL-40). Nonspecific binding was less than 2.0%.

% Nonspecificity = (nonspecific signal / specific signal) x 100

Diluent Compatibility

Diluents 57 and 3 are provided with this assay. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested.

Assay Components

Calibrator: I-309 is included in Calibrator 10 The I-309 Calibrator is a full-length recombinant protein expressed in E. coli.

Antibodies: The U-PLEX Human I-309 Assay uses a mouse monoclonal antibody for capture and a rabbit polycloncal antibody for detection.

Assay generation: B

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently from the representative data shown.



MESO SCALE DISCOVERY, Meso Scale Diagnostics, www.mesoscale.com, MSD, MSD (design), QuickPlex, SECTOR, U-PLEX, U-PLEX (design), 96 WELL SMALL-SPOT (design), and Spot the Difference are trademarks and/or service marks of Meso Scale Diagnostics, LLC. ©2016-2023 Meso Scale Diagnostics, LLC. All rights reserved.